Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news > Benefit-Risk Assessment for New Drug and Biological Products – Guidance for Industry
USA-Guidance-for-Industry-Benefit-Risk-Assessment-for-New-Drug-and-Biological-Products-19Oct-2023-1Download
Ryan McArthur 23 October 2023 All news
  • ← EMA – Mid-year report 2023
  • Early access to medicines: a positive assessment after two years of implementation →

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

In partnership with the region

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28-31 October 2024
  • Questions and Answers on the Windsor Framework and medicines for human use (updated 25 October 2024)
  • Annual report of the Pharmacovigilance Inspectors’ Working Group for 2023
Copyright © 2018 - Pharmya - Legal terms - Quality Policy